Drug Type Chemical drugs |
Synonyms- |
Target |
Mechanism PSMB5 inhibitors(proteasome 20S subunit beta 5 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Graft Rejection | Preclinical | DE | 20 Apr 2023 | |
Graft Rejection | Preclinical | DE | 20 Apr 2023 | |
Infectious Diseases | Preclinical | DE | 20 Apr 2023 | |
Infectious Diseases | Preclinical | DE | 20 Apr 2023 | |
Inflammation | Preclinical | DE | 20 Apr 2023 | |
Inflammation | Preclinical | DE | 20 Apr 2023 | |
Myasthenia Gravis | Preclinical | DE | 20 Apr 2023 | |
Myasthenia Gravis | Preclinical | DE | 20 Apr 2023 |